Boothbay Fund Management, LLC Otonomy, Inc. Transaction History

Boothbay Fund Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.72 - $2.51 $36,202 - $52,830	-21,048 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $3,861 - $6,963	-3,165 Reduced 13.07%	21,048 $40,000
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $49,878 - $64,648	24,213 New	24,213 $54,000
Q1 2021 May 17, 2021	SELL	$2.49 - $6.23 $159,800 - $399,822	-64,177 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$3.48 - $6.47 $25,431 - $47,282	-7,308 Reduced 10.22%	64,177 $415,000
Q3 2020 Nov 16, 2020	SELL	$3.16 - $4.36 $323,489 - $446,333	-102,370 Reduced 58.88%	71,485 $290,000
Q2 2020 Aug 14, 2020	SELL	$1.87 - $3.84 $91,385 - $187,656	-48,869 Reduced 21.94%	173,855 $629,000
Q1 2020 May 15, 2020	BUY	$1.58 - $4.06 $54,745 - $140,674	34,649 Added 18.42%	222,724 $439,000
Q2 2019 Aug 14, 2019	BUY	$2.35 - $3.09 $4,869 - $6,402	2,072 Added 1.11%	188,075 $517,000
Q1 2019 May 15, 2019	BUY	$1.8 - $2.97 $334,805 - $552,428	186,003 New	186,003 $489,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.